| Name | Title | Contact Details |
|---|
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.
Teknova offers custom molecular biology media such as buffers and reagents, pre-poured agar plates, dry culture media, liquid culture media, and media supplements.
iCyt is a profitable, innovative, bioscience technology company that will contribute to its community by: delivering novel cell measurement and handling technologies that enable our clients to create important new healthcare and agriculture
Helsinn Therapeutics (US) is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.